NCT06263010View on ClinicalTrials.gov

Allopregnanolone As a Regenerative Treatment for Parkinson's Disease

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 12, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

May 31, 2025

Conditions

Parkinson Disease

Interventions

DRUG

Allopregnanolone

Allopregnanolone is a neurosteroid ( 3α,5α-tetrahydroprogesterone, 3α-hydroxy-5α-pregnan-20-one) and by-product of the metabolism of the hormone progesterone.

Trial Locations (1)

85721

The University of Arizona Clinical & Translational Science Research Center, Tucson

All Listed Sponsors

lead

Roberta Brinton

OTHER

NCT06263010 - Allopregnanolone As a Regenerative Treatment for Parkinson's Disease | Biotech Hunter | Biotech Hunter